Curcumin Derivative Crystal Form I for Stable Kidney Drug Formulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diabetic nephropathy are unsatisfactory, particularly in the early stages, as they cannot reverse kidney damage or halt its progression to end-stage renal disease, and existing curcumin derivatives lack suitable crystal forms for effective drug formulation.
Innovation Solution
Development of a stable crystal form I of a curcumin derivative (C66) with specific X-ray powder diffraction peaks and a preparation method involving solvent crystallization, which allows for large-scale production and improved drug-forming properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (lowering blood sugar, blood pressure, blood lipid) are used for early diabetic nephropathy, then kidney damage can be delayed, but kidney damage cannot be reversed and progression to ESRD cannot be stopped
Solution Approach 1:
The patent changes the chemical structure parameters of curcumin by introducing specific substituents (methyl groups at positions 2 and 6, carbonyl group at position 3) to create curcumin-2,6-dimethyl-3-one derivative. This structural parameter change enhances the compound's ability to inhibit NF-κB signaling and reduce inflammation, thereby reversing kidney damage and halting progression to ESRD, overcoming the limitations of conventional treatments.
Solution Approach 2:
The patent creates a composite therapeutic approach by combining curcumin-2,6-dimethyl-3-one derivative with specific crystal forms (Form I and Form II) that have optimized physical properties. This composite material approach enhances the drug's bioavailability and therapeutic effectiveness, enabling reversal of kidney damage while addressing the limitations of conventional single-mechanism treatments.
2Reliability
If curcumin derivative is used for treating diabetic nephropathy, then therapeutic efficacy is improved, but suitable crystal forms for drug formulation are lacking
Solution Approach 1:
The patent systematically varies crystal formation parameters by testing multiple solvents (methanol, ethanol, acetone, isopropanol, ethyl acetate, toluene, acetonitrile, methyl tert-butyl ether, isopropyl acetate, heptane, methyl isobutyl ketone) and processing conditions. This parameter optimization yielded two suitable crystal forms (Form I and Form II) with appropriate physical properties for drug formulation, resolving the shortage of suitable crystal forms for curcumin derivatives.
Solution Approach 2:
The patent utilizes phase transition processes (crystallization from liquid solvents to solid crystal forms) to transform curcumin derivative into suitable pharmaceutical forms. By controlling the phase transition during crystallization, the patent produced crystal forms with optimized solubility, stability, and flow properties, enabling effective drug formulation while maintaining therapeutic efficacy.
3Ease of manufacture
If multiple crystal forms are obtained through solvent crystallization, then drug-forming properties are improved, but production scalability is limited
Solution Approach 1:
The patent optimizes crystallization parameters by identifying specific solvent systems and processing conditions that favor the formation of crystal Form I. By tuning parameters such as solvent choice, temperature, concentration, and cooling rate, the patent achieved both high-quality crystal formation and scalable production, resolving the contradiction between drug-forming properties and production scalability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystal form I of C66 exhibits better fluidity, stability, and solubility, making it suitable for drug formulation and effective in treating diabetic nephropathy and other chronic kidney diseases.
Implementation Method 1
a preparation method involving solvent crystallization
Implementation Method 2
slowly evaporating the filtrate at room temperature and humidity, precipitating crystals
Implementation Method 3
X-ray powder diffraction pattern of which contains following characteristic peaks for 20 reflection angle determination
Implementation Method 4
X-ray powder diffraction pattern
Data Source
AI summary
Provided are a crystal form I of a curcumin derivative (C66), a preparation method therefor and an application thereof. An X-ray powder diffraction pattern of the crystal form I contains following characteristic peaks for 2θ reflection angle determination: 8.4±0.2°, 11.5±0.2°, 13.1±0.1°, 16.6±0.2°, 18.8±0.1°, and 21.2±0.1°. No sharp diffraction peak exists at 33.5±0.2° and 38.1±0.2°. A structure of the curcumin derivative is shown in formula (I) as follows: